Sabine[a]
Wer kennt REOLYSIN ??? Soll ein experimentelles Mediakment gegen Hirntumore sein.
Unterstützen Sie unsere Arbeit für Hirntumorpatienten. Jeder Beitrag hilft.
Sabine[a]
Wer kennt REOLYSIN ??? Soll ein experimentelles Mediakment gegen Hirntumore sein.
Peter[a]
Wenn Du nach "Reolysin" in der Datenbank suchst, findest du mindestens drei Artikel.
Mike[a]
Studie I/II ergab:
None of the patients receiving REOLYSIN® experienced any serious adverse events related to the virus, nor were there any dose-limiting toxicities detected in any patient.
The secondary outcome was tumour response. Eleven of 18 patients (61%) showed evidence of viral activity with tumour regression ranging from 32% to 100%. (Viral activity is defined as a transitory or lasting tumour regression of at least 30% measured in two dimensions against the tumour size prior to injection on the first day of treatment.) Clinically, tumour response is classified in one of four ways:
Progressive disease - tumour growth of greater than 25%
Stable disease - change ranges from growth of less than 25% to a reduction of less than 50%
Partial response - a reduction of greater than 50% but there is still detectable tumour
Complete response - no tumour can be detected
Patients are considered to be evaluable for clinical response only if they return for all follow-ups. In 11 of 17 evaluable patients, the injected tumours were classified as stable disease on day 28 after the first, and in some cases the only injection of REOLYSIN®. By day ninety-eight, at the conclusion of the trial, five of 10 evaluable patients still had tumour responses (four stable disease, one partial response). In addition, evidence of remote tumour response was also noted in several patients, suggesting a potential role in the treatment of metastases.
Also ein vielverprechendes Ergebnis!